Subject(s)
Antibodies, Monoclonal, Humanized , Glucocorticoids , Lupus Erythematosus, Systemic , Administration, Intravenous , Adult , Antibodies, Antinuclear/blood , Antibodies, Antiphospholipid/blood , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Dose-Response Relationship, Drug , Drug Monitoring , Drug Therapy, Combination/methods , Female , Follow-Up Studies , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Italy , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/physiopathology , Patient Acuity , Treatment OutcomeSubject(s)
Behcet Syndrome/epidemiology , Emigrants and Immigrants/statistics & numerical data , Adolescent , Adult , Female , Humans , Italy/epidemiology , Male , Prevalence , Young AdultABSTRACT
OBJECTIVES: We retrospectively compared disease activity, treatment, clinical and laboratory features, and rate of mortality of 535 SLE patients with adult and late disease onset. METHODS: patients were divided into two groups based on the onset of the disease before or after 50 years of age. Clinical data were collected from medical reports. Disease activity was measured by ECLAM score. Parameters were compared by χ²-test, Fisher's test, Student's t or the Mann-Whitney test. RESULTS: Forty patients (7.5%) were included in the late SLE onset group (group A), while 495 (92.5%) in the adult SLE onset group (group B). Sicca symptoms were more frequent in group A (p < 0.0008), while glomerulonephritis (p < 0.0069), reduced C3 (p < 0.0006) and low C3 (p < 0.00002) and C4 levels (p < 0.0006) were more prevalent in group B. Twenty-two deaths (4.3%) were recorded: 14 (2.8%) in group B and 8 (20%) in group A. Deaths were mainly due to infections in group B (28.5%) and cardiovascular events in group A (50%). A lower use of HCQ and LDA were recorded in deceased versus living patients (p < 0.0001 and 0.0166, respectively), while a higher ECLAM score was measured at onset in dead versus living patients (p < 0.048). CONCLUSIONS: Late onset SLE occurred in 7.5% of patients and it was associated with sicca symptoms. The use of HCQ and LDA is positively correlated with survival. Death in late onset SLE occurred more frequently for cardiovascular involvement. Higher disease activity at onset of the disease might represent a poor prognostic factor for death in adult onset.
